Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 5/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426367 | 0.88 | LHCGR (0.55) | BRAFMAPTMEN1KMT2A | |
| SCHEMBL5024685 | 0.85 | BRAF (0.58) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL4419064 | 0.82 | BRAF (0.64) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL5026134 | 0.81 | BRAF (0.51) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL4425936 | 0.81 | BRAF (0.58) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL4425219 | 0.81 | BRAF (0.55) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL5026948 | 0.79 | BRAF (0.52) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4421671 | 0.78 | BRAF (0.51) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL6217358 | 0.78 | LHCGR (0.57) | BRAFIKBKBPDE4APDE4BPDE4C | |
| SCHEMBL5026192 | 0.76 | BRAF (0.48) | BRAFIKBKBPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | claimed |
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1886999-A2 | Bicyclic heteroaromatic compound | N.V. Organon (NL) | 2008-02-13 | — | — | EP | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | BRAF 4474/4885IKBKB 1808/4885PDE4A 1417/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | BRAF 4242/4885IKBKB 2570/4885PDE4A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.